Inj cyclophos frindovyx 5 mg
Products billed under this code include Cyclophosphamide, Frindovyx.
Payment limit per 5 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cyclophosphamide, Frindovyx.
Payment limit per 5 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyclophosphamide | Avyxa Pharma, LLC | 83831-0116-01 | 100 | $812.00 |
| Cyclophosphamide | Avyxa Pharma, LLC | 83831-0117-02 | 200 | $1,624.00 |
| Cyclophosphamide | Avyxa Pharma, LLC | 83831-0118-04 | 400 | $3,248.00 |
| Frindovyx | Avyxa Pharma, LLC | 83831-0119-01 | 100 | $812.00 |
| Frindovyx | Avyxa Pharma, LLC | 83831-0120-02 | 200 | $1,624.00 |
| Frindovyx | Avyxa Pharma, LLC | 83831-0121-04 | 400 | $3,248.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $8.12 | −$0.802 | 5 MG | Inj cyclophos frindovyx 5 mg | v1, posted September 17, 2026 |
| 3Q26 | $8.922 | −$0.181 | 5 MG | Inj cyclophos frindovyx 5 mg | v1, posted September 15, 2026 |
| 2Q26 | $9.103 | +$0.112 | 5 MG | Inj cyclophos frindovyx 5 mg | v1, posted September 15, 2026 |
| 1Q26 | $8.991 | −$0.114 | 5 MG | Inj cyclophos frindovyx 5 mg | v1, posted September 15, 2026 |
| 4Q25 | $9.105 | +$0.102 | 5 MG | Inj cyclophos frindovyx 5 mg | v1, posted September 8, 2026 |
| 3Q25 | $9.003 | −$0.05 | 5 MG | Inj cyclophos avyxa 5mg | v1, posted March 10, 2026 |
| 2Q25 | $9.053 | – | 5 MG | Inj cyclophos avyxa 5mg | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.